Skip to main content
. 2019 Jul 3;33(4):1355–1362. doi: 10.21873/invivo.11611

Table II. Regimen details for patients with haematological malignancies who received HEC or MEC.

graphic file with name in_vivo-33-1357-i0002.jpg

ABVD, Doxorubicin, bleomycin, vinblastine, and dacarbazine; CHOP, cyclophosphamide, doxorubicin, vincristine, and prednisolone; HEC, highly emetogenic chemotherapy; MEC, moderately emetogenic chemotherapy; VCD, bortezomib, cyclophosphamide, and dexamethasone.